Clin Psychopharmacol Neurosci.
2022 Feb;20(1):37-50. 10.9758/cpn.2022.20.1.37.
The Korean Medication Algorithm Project for Depressive Disorder 2021: Comparisons with Other Treatment Guidelines
- Woo YS
1 - Bahk WM1
- Seo JS2
- Park YM3
- Kim W4
- Jeong JH1
- Shim SH5
- Lee JG6
- Jang SH7
- Yang CM7
- Wang SM1
- Jung MH8
- Sung HM9
- Choo IH10
- Yoon BH11
- Lee SY7
- Jon DI8
- Min KJ2
- Affiliations
-
- 1Department of Psychiatry, College of Medicine, The Catholic University of Korea, Seoul, Korea.
- 2Department of Psychiatry, College of Medicine, Chung-Ang University, Seoul, Korea.
- 3Department of Psychiatry, Ilsan Paik Hospital, Inje University College of Medicine, Goyang, Korea.
- 4Department of Psychiatry, Sanggye Paik Hospital, Inje University College of Medicine, Seoul, Korea.
- 5Department of Psychiatry, Soonchunhyang University Cheonan Hospital, College of Medicine, Soonchunhyang University, Cheonan, Korea.
- 6Department of Psychiatry, Haeundae Paik Hospital, College of Medicine, Inje University, Busan, Korea.
- 7Department of Psychiatry, Wonkwang University Hospital, School of Medicine, Wonkwang University, Iksan, Korea.
- 8Department of Psychiatry, Hallym University Sacred Heart Hospital, Hallym University College of Medicine, Anyang, Korea.
- 9Department of Psychiatry, Soonchunhyang University Gumi Hospital, College of Medicine, Soonchunhyang University, Gumi, Korea.
- 10Department of Neuropsychiatry, College of Medicine, Chosun University, Department of Psychiatry, Chosun University Hospital, Gwangju, Korea.
- 11Department of Psychiatry, Naju National Hospital, Naju, Korea.
- KMID: 2526846
- DOI: http://doi.org/10.9758/cpn.2022.20.1.37
Abstract
- The Korean Medication Algorithm Project for Depressive Disorder (KMAP-DD) first was published in 2002, and has been revised four times, in 2006, 2012, 2017, and 2021. In this review, we compared recommendations from the recently revised KMAP-DD 2021 to four global clinical practice guidelines (CPGs) for depression published after 2010. The recommendations from the KMAP-DD 2021 were similar to those from other CPGs, although there were some differences. The KMAP-DD 2021 reflected social culture and the healthcare system in Korea and recent evidence about pharmacotherapy for depression, as did other recently published evidence-based guidelines. Despite some intrinsic limitations as an expert consensus-based guideline, the KMAP-DD 2021 can be helpful for Korean psychiatrists making decisions in clinical settings by complementing previously published evidence-based guidelines, especially for some clinical situations lacking evidence from rigorously designed clinical trials.
Keyword
- Full Text Links
-
- Actions
-
Cited
- CITED
-
- Close
- Share
-
- Similar articles
-
- The Development of Korean Medication Algorithm for Major Psychiatric Disorder
- Korean Medication Algorithm Project for Bipolar Disorder 2022: Comparisons with Other Treatment Guidelines
- Korean Medication Algorithm for Depressive Disorder: Comparisons with Other Treatment Guidelines
- Korean Medication Algorithm Project for Depressive Disorder 2021 (III): Child and Adolescent
- The Consideration for Revision of the Korean Medication Algorithm for Schizophrenia
